Aortic Valve Stenosis Clinical Trial
Official title:
Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement
The purpose of the study is to investigate the superiority of chronic left bundle branch area pacing compared to traditional right ventricular (RV) septal pacing in patients with high-grade conduction disease after transcatheter aortic valve replacement (TAVR). In this investigator initiated, multicenter, prospective, double-blinded, crossover study, chronic left bundle branch area pacing will be compared to chronic right ventricular septal pacing using echocardiographic measures of left ventricular systolic function in patients with a high cumulative ventricular pacing burden after TAVR.
Status | Recruiting |
Enrollment | 46 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject has at least one of these conduction disturbances: 1. Symptomatic (or hemodynamically significant) bradycardia or symptomatic persistent atrioventricular block including first-degree and Mobitz I (Wenckebach) or Mobitz type II atrioventricular bock 2. High-grade atrioventricular block 3. Third-degree atrioventricular block - Subject has undergone TAVR (any valve system) in the last four weeks - Subject is receiving a first-time pacemaker implant - Subject's most recent documented ejection fraction (by any method) within the past 90 days prior to study enrollment is > 50% (=45% if visually estimated at the time of enrollment) - Subject is a male or female at least 18 years old at the time of consent - Subject is able to receive a left sided pectoral implant Exclusion Criteria: - Subject has ever had a previous or has an existing implantable pulse generator (IPG), implantable cardiac defibrillator (ICD) or biventricular (BiV) implant - Subject has more than mild para-valvular regurgitation following TAVR implantation. - Subject has LVEF < 45% if visually estimated at the time of enrollment - Subject is indicated for a biventricular pacing device (CRT-P or CRT-D). - Subject is enrolled in a concurrent study that may confound the results of this study - Subject has a mechanical heart valve - Subject is pregnant, or of childbearing potential and not on a reliable form of birth control - Subject status post heart transplant - Subject life expectancy less than 2 years |
Country | Name | City | State |
---|---|---|---|
United States | Kansas City Heart Rhythm Institute | Overland Park | Kansas |
United States | Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Valley Health System | Ridgewood | New Jersey |
United States | Lankenau Medical Center | Wynnewood | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Main Line Health | Medtronic, Sharpe-Strumia Research Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in global longitudinal strain (GLS%) | Primary efficacy outcome | 9 months | |
Primary | Change in left ventricular ejection fraction (LVEF%) | Primary efficacy outcome | 9 months | |
Primary | Composite of left bundle branch area pacing lead septal myocardial or coronary artery perforation, lead dislodgment, and repeat procedures related to left bundle branch area lead implantation | Primary safety endpoint | 18 months | |
Secondary | Adverse events related to device function | 18 months | ||
Secondary | Quality of life measured using the Minnesota Living with Heart Failure questionnaire (MLHQ) | 9 months | ||
Secondary | Functional capacity measured using the New York Heart Association functional classification (NYHA) | 9 months | ||
Secondary | Six minute walk test score | 9 months | ||
Secondary | Hospitalizations for heart failure | 18 months | ||
Secondary | Mortality | 18 months | ||
Secondary | Right ventricular global longitudinal strain (RVGLS%) | 9 months | ||
Secondary | Left ventricular mechanical systolic dyssynchrony indexed to heart rate (SDI) | 9 months | ||
Secondary | Interventricular mechanical delay (IVMD) | 9 months | ||
Secondary | Left ventricular end-systolic volume | 9 months | ||
Secondary | Left ventricular stroke volume | 9 months | ||
Secondary | Severity of tricuspid regurgitation | 18 months | ||
Secondary | Severity of mitral regurgitation | 18 months | ||
Secondary | Left bundle branch area pacing lead pacing threshold | 18 months | ||
Secondary | Left bundle branch area pacing lead sensed R wave amplitude | 18 months | ||
Secondary | Left bundle branch area pacing lead impedence | 18 months | ||
Secondary | Brain natriuretic peptide or N-terminal pro-brain natriuretic peptide concentration | 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|